Ventana Biotech, Inc.
VNTA · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 9.89 | 0.16 | -4.73 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 0.00 | -3,989.70 | -134.05 | 0.00 |
| Quality | ||||
| ROIC | 0.00% | -2.70% | -7.75% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -1.22 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 20.02% | 156.82% | 345,733.59% | 387,056.62% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -32.55 | -13.36 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -91.71 | -433.13 | 0.00 |